SE9900100D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9900100D0
SE9900100D0 SE9900100A SE9900100A SE9900100D0 SE 9900100 D0 SE9900100 D0 SE 9900100D0 SE 9900100 A SE9900100 A SE 9900100A SE 9900100 A SE9900100 A SE 9900100A SE 9900100 D0 SE9900100 D0 SE 9900100D0
Authority
SE
Sweden
Prior art keywords
new compounds
sub
compounds
psychotic
formula
Prior art date
Application number
SE9900100A
Other languages
English (en)
Swedish (sv)
Inventor
Iii James T Loch
George Mullen
Eifion Phillips
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9900100A priority Critical patent/SE9900100D0/xx
Publication of SE9900100D0 publication Critical patent/SE9900100D0/xx
Priority to IDW00200101529A priority patent/ID30034A/id
Priority to TR2001/02042T priority patent/TR200102042T2/xx
Priority to ES99967044T priority patent/ES2200590T3/es
Priority to HK02102161.7A priority patent/HK1040517B/en
Priority to NZ512733A priority patent/NZ512733A/en
Priority to CA002359990A priority patent/CA2359990A1/en
Priority to AT99967044T priority patent/ATE240960T1/de
Priority to KR1020017008939A priority patent/KR100660496B1/ko
Priority to CN998164224A priority patent/CN1132837C/zh
Priority to RU2001122812/04A priority patent/RU2233282C2/ru
Priority to EP99967044A priority patent/EP1147114B1/de
Priority to AU23343/00A priority patent/AU775433B2/en
Priority to IL14426699A priority patent/IL144266A0/xx
Priority to US09/529,654 priority patent/US6995167B2/en
Priority to PT99967044T priority patent/PT1147114E/pt
Priority to BR9916906-1A priority patent/BR9916906A/pt
Priority to UA2001085777A priority patent/UA71598C2/uk
Priority to JP2000593611A priority patent/JP2002534525A/ja
Priority to DK99967044T priority patent/DK1147114T3/da
Priority to HU0200513A priority patent/HUP0200513A3/hu
Priority to DE69908185T priority patent/DE69908185T2/de
Priority to CZ20012554A priority patent/CZ20012554A3/cs
Priority to PCT/SE1999/002478 priority patent/WO2000042044A1/en
Priority to SI9930375T priority patent/SI1147114T1/xx
Priority to SK993-2001A priority patent/SK9932001A3/sk
Priority to EEP200100370A priority patent/EE04528B1/xx
Priority to MYPI20000100A priority patent/MY118109A/en
Priority to ARP000100156A priority patent/AR022283A1/es
Priority to TW089100989A priority patent/TWI227237B/zh
Priority to TW093106537A priority patent/TW200413387A/zh
Priority to SA00200987A priority patent/SA00200987B1/ar
Priority to ZA200105527A priority patent/ZA200105527B/en
Priority to IS6000A priority patent/IS6000A/is
Priority to NO20013478A priority patent/NO20013478L/no
Priority to US11/181,098 priority patent/US7196096B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SE9900100A 1999-01-15 1999-01-15 New compounds SE9900100D0 (sv)

Priority Applications (36)

Application Number Priority Date Filing Date Title
SE9900100A SE9900100D0 (sv) 1999-01-15 1999-01-15 New compounds
EEP200100370A EE04528B1 (et) 1999-01-15 1999-12-23 Teraapias kasutatavad spirofuropridiinide aralklamiinid
BR9916906-1A BR9916906A (pt) 1999-01-15 1999-12-23 Composto, composição farmacêutica, uso de umcomposto, métodos de tratamento ou profilaxiade, distúrbios psicóticos ou distúrbios deenfraquecimento intelectual, e de tratamento ouprofilaxia de doenças ou condições humanas emque a ativação do receptor alfa-7 nicotìnico ébenéfica, e, processo para preparar um composto
UA2001085777A UA71598C2 (en) 1999-01-15 1999-12-23 Furopiridines aralkilamines, a pharmaceutical composition based thereon, a method for the preparation thereof and furopiridine derivatives
ES99967044T ES2200590T3 (es) 1999-01-15 1999-12-23 Nuevas aralquilaminas de espirofuropiridinas utiles en terapia.
HK02102161.7A HK1040517B (en) 1999-01-15 1999-12-23 New spirofuropyridine aralkylamines useful in therapy
NZ512733A NZ512733A (en) 1999-01-15 1999-12-23 Aralkyl amines of spirofuropyridines useful in treating psychotic and intellectual impairment disorders
CA002359990A CA2359990A1 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
AT99967044T ATE240960T1 (de) 1999-01-15 1999-12-23 Therapeutisch nützliche arylalkylamine von spirofuropyridinen
KR1020017008939A KR100660496B1 (ko) 1999-01-15 1999-12-23 치료에 유용한 스피로푸로피리딘의 신규 아랄킬 아민
CN998164224A CN1132837C (zh) 1999-01-15 1999-12-23 螺呋喃并吡啶芳烷基胺、其制法和中间体及其药物组合物和制药用途
RU2001122812/04A RU2233282C2 (ru) 1999-01-15 1999-12-23 Аралкиламины фуропиридинов, способ их получения, фармацевтическая композиция на их основе и промежуточные вещества
EP99967044A EP1147114B1 (de) 1999-01-15 1999-12-23 Therapeutisch nützliche arylalkylamine von spirofuropyridinen
AU23343/00A AU775433B2 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
IL14426699A IL144266A0 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
US09/529,654 US6995167B2 (en) 1999-01-15 1999-12-23 Arylkylamine spirofuropyridines useful in therapy
PT99967044T PT1147114E (pt) 1999-01-15 1999-12-23 Novos aralquilaminas de espirofuropiridinas uteis em terapia.
IDW00200101529A ID30034A (id) 1999-01-15 1999-12-23 Aralkil amina baru dari spirofuropiridin yang berguna dalam terapi
JP2000593611A JP2002534525A (ja) 1999-01-15 1999-12-23 治療において有用なスピロフロピリジンの新規なアラルキルアミン
TR2001/02042T TR200102042T2 (tr) 1999-01-15 1999-12-23 Spiro fropiridinlerin, tedavide faydalı yeni aralkil aminleri.
DK99967044T DK1147114T3 (da) 1999-01-15 1999-12-23 Hidtil ukendt aralkylaminer af spirofuropyridiner, der er egnede til terapi
HU0200513A HUP0200513A3 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy, process for their preparation, pharmaceutical compositions containing them and their use
DE69908185T DE69908185T2 (de) 1999-01-15 1999-12-23 Therapeutisch nützliche arylalkylamine von spirofuropyridinen
CZ20012554A CZ20012554A3 (cs) 1999-01-15 1999-12-23 Nové aralkylaminy spirofuropyridinů vhodné pro léčení
PCT/SE1999/002478 WO2000042044A1 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
SI9930375T SI1147114T1 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
SK993-2001A SK9932001A3 (en) 1999-01-15 1999-12-23 Novel aralkyl amines of spirofuropyridines useful in therapy
ARP000100156A AR022283A1 (es) 1999-01-15 2000-01-13 Aminas substituidas de espirofuropiridinas novedosas utiles en terapia
MYPI20000100A MY118109A (en) 1999-01-15 2000-01-13 Novel aralkyl amines of spirofuropyridines useful in therapy
TW089100989A TWI227237B (en) 1999-01-15 2000-01-21 Novel aralkyl amines of spirofuropyridines useful in therapy
TW093106537A TW200413387A (en) 1999-01-15 2000-01-21 Novel intermediates for preparing aralkyl amines of spirofuropyridines useful in therapy
SA00200987A SA00200987B1 (ar) 1999-01-15 2000-02-21 Aralkyl Amines جديدة من Spirofuropyridines مفيدة في العلاج
ZA200105527A ZA200105527B (en) 1999-01-15 2001-07-04 Novel aralkyl amines of spirofuropyridines useful in therapy.
IS6000A IS6000A (is) 1999-01-15 2001-07-12 Ný aralkýlamín af spírófúrópýridínum sem nytsamleg eru í meðferð
NO20013478A NO20013478L (no) 1999-01-15 2001-07-13 Nye aralkylaminer av spirofuropyridiner som er nyttige i terapi
US11/181,098 US7196096B2 (en) 1999-01-15 2005-07-14 Substituted amines of spirofuropyridines useful in therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900100A SE9900100D0 (sv) 1999-01-15 1999-01-15 New compounds

Publications (1)

Publication Number Publication Date
SE9900100D0 true SE9900100D0 (sv) 1999-01-15

Family

ID=20414101

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9900100A SE9900100D0 (sv) 1999-01-15 1999-01-15 New compounds

Country Status (34)

Country Link
US (2) US6995167B2 (de)
EP (1) EP1147114B1 (de)
JP (1) JP2002534525A (de)
KR (1) KR100660496B1 (de)
CN (1) CN1132837C (de)
AR (1) AR022283A1 (de)
AT (1) ATE240960T1 (de)
AU (1) AU775433B2 (de)
BR (1) BR9916906A (de)
CA (1) CA2359990A1 (de)
CZ (1) CZ20012554A3 (de)
DE (1) DE69908185T2 (de)
DK (1) DK1147114T3 (de)
EE (1) EE04528B1 (de)
ES (1) ES2200590T3 (de)
HK (1) HK1040517B (de)
HU (1) HUP0200513A3 (de)
ID (1) ID30034A (de)
IL (1) IL144266A0 (de)
IS (1) IS6000A (de)
MY (1) MY118109A (de)
NO (1) NO20013478L (de)
NZ (1) NZ512733A (de)
PT (1) PT1147114E (de)
RU (1) RU2233282C2 (de)
SA (1) SA00200987B1 (de)
SE (1) SE9900100D0 (de)
SI (1) SI1147114T1 (de)
SK (1) SK9932001A3 (de)
TR (1) TR200102042T2 (de)
TW (2) TWI227237B (de)
UA (1) UA71598C2 (de)
WO (1) WO2000042044A1 (de)
ZA (1) ZA200105527B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
BR0210075A (pt) * 2001-06-01 2004-08-17 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou distúrbios da debilitação intelectual e de fadiga de vÈo, cessamento de fumar, dependência de nicotina, dores, e para a colite ulcerativa
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
CA2462453C (en) * 2001-10-02 2009-07-28 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
ES2348282T3 (es) * 2002-04-18 2010-12-02 Astrazeneca Ab Compuestos de tienilo.
US7417049B2 (en) * 2002-04-18 2008-08-26 Astrazeneca Ab Furyl compounds
NZ561993A (en) * 2002-04-18 2008-09-26 Astrazeneca Ab Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors
US7244745B2 (en) 2002-08-30 2007-07-17 Memory Pharmaceuticals Corp. Heterocyclic compounds, methods for the preparation thereof, and uses thereof
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
JP4750421B2 (ja) * 2002-12-06 2011-08-17 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
EP1598355A4 (de) * 2003-01-08 2010-01-27 Mitsubishi Tanabe Pharma Corp Therapeutischer wirkstoff zur behandlung von schizophrenie
US20050129610A1 (en) * 2003-06-24 2005-06-16 Johns Hopkins University Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor
BRPI0415546A (pt) 2003-10-21 2006-12-26 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
EP1735306A2 (de) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazole, benzothiazole, benzoisothiazole, benzisoxazole und deren herstellung und verwendungen
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
RU2448111C2 (ru) * 2006-08-21 2012-04-20 Дженентек, Инк. Соединения азабензофуранила и способ их применения
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN102131791B (zh) 2008-06-20 2014-12-24 阿斯利康(瑞典)有限公司 二苯并硫杂氮杂*衍生物及其用途
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
LT2889033T (lt) 2008-11-19 2018-07-10 Forum Pharmaceuticals Inc. Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) * 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
HK1205114A1 (en) 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
EP3461481A1 (de) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Verfahren zur aufrechterhaltung, behandlung oder verbesserung der kognitiven funktion
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
WO2014202999A1 (en) 2013-06-21 2014-12-24 Takeda Cambridge Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853758T2 (de) * 1987-10-05 1995-09-07 Yamanouchi Pharma Co Ltd Heterozyklische Spiroverbindungen und ihre Herstellung.
JPH0195922A (ja) 1987-10-08 1989-04-14 Mazda Motor Corp 車両のサスペンション制御装置
SU1540240A1 (ru) * 1988-05-16 1995-09-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 5-ЗАМЕЩЕННЫЕ 1-АМИНО -8,9-ДИГИДРО -8,8-ДИМЕТИЛ-3, 6Н- ПИРАЗОЛО [3,4-B] ПИРАНО[[4′,3′-d]] ПИРИДИНА ИЛИ ИХ ГИДРОХЛОРИДЫ, ОБЛАДАЮЩИЕ ПРОТИВОСУДОРОЖНОЙ АКТИВНОСТЬЮ
ATE192157T1 (de) * 1994-08-24 2000-05-15 Astra Ab Therapeutisch verwendbare spiro-azabicyclische verbindungen
EP0842178B1 (de) * 1995-07-28 2001-03-28 Abbott Laboratories Furo-, thieno- und pyrrolopyridine und verwandte pyrinidin-, pyridazin- und triazinverbindungen verwendbar zur kontrolle von chemische synaptische übertragung
US6156783A (en) 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
TW200413387A (en) 2004-08-01
US7196096B2 (en) 2007-03-27
CA2359990A1 (en) 2000-07-20
ES2200590T3 (es) 2004-03-01
UA71598C2 (en) 2004-12-15
IL144266A0 (en) 2002-05-23
NZ512733A (en) 2003-08-29
JP2002534525A (ja) 2002-10-15
DE69908185D1 (de) 2003-06-26
KR20010086167A (ko) 2001-09-08
ATE240960T1 (de) 2003-06-15
CZ20012554A3 (cs) 2002-01-16
ZA200105527B (en) 2002-10-04
DE69908185T2 (de) 2004-06-03
ID30034A (id) 2001-11-01
EP1147114A1 (de) 2001-10-24
SA00200987B1 (ar) 2006-11-07
MY118109A (en) 2004-08-30
NO20013478D0 (no) 2001-07-13
RU2233282C2 (ru) 2004-07-27
AU2334300A (en) 2000-08-01
KR100660496B1 (ko) 2006-12-22
TWI227237B (en) 2005-02-01
EE200100370A (et) 2002-10-15
EP1147114B1 (de) 2003-05-21
AR022283A1 (es) 2002-09-04
HK1040517B (en) 2003-09-05
SK9932001A3 (en) 2002-04-04
NO20013478L (no) 2001-09-14
HK1040517A1 (en) 2002-06-14
HUP0200513A2 (en) 2002-06-29
US6995167B2 (en) 2006-02-07
TR200102042T2 (tr) 2002-05-21
PT1147114E (pt) 2003-10-31
WO2000042044A1 (en) 2000-07-20
BR9916906A (pt) 2001-10-30
US20030149065A1 (en) 2003-08-07
US20050250802A1 (en) 2005-11-10
DK1147114T3 (da) 2003-09-15
CN1337964A (zh) 2002-02-27
IS6000A (is) 2001-07-12
SI1147114T1 (en) 2003-12-31
HUP0200513A3 (en) 2004-07-28
EE04528B1 (et) 2005-08-15
CN1132837C (zh) 2003-12-31
AU775433B2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
SE9900100D0 (sv) New compounds
DE60112974D1 (en) Carbolinderivate
CO5271691A1 (es) Nuevos compuestos
GB9801690D0 (en) Therapeutic agents
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
DK1112106T3 (da) Serotonerge 5HT2-agonister til behandling af glaukom
SE9904176D0 (sv) New use
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
GB9929552D0 (en) Compounds
DE60216233D1 (en) Carbolinderivate
AU2001266575A1 (en) Chemical compounds
MXPA03002911A (es) Compuestos quimicos.
MXPA02012076A (es) Compuestos quimicos.
GB0114185D0 (en) Compounds
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
SE9904765D0 (sv) Pharmaceutically-useful compounds
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
SE0003476D0 (sv) Compounds
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
DK1532131T3 (da) Motilid-forbindelser
PT1204659E (pt) Benzofuranos serotoninergicos
ATE259813T1 (de) Triazolopyrimidinderivate
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
ATE280169T1 (de) Serotonerge benzothiophene